- Home
- TNGX vs FAASW Comparison
TNGX vs FAASW Comparison
Compare TNGX & FAASW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- FAASW
- Stock Information
- Founded
- TNGX 2014
- FAASW N/A
- Country
- TNGX United States
- FAASW United States
- Employees
- TNGX N/A
- FAASW N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- FAASW
- Sector
- TNGX Health Care
- FAASW
- Exchange
- TNGX Nasdaq
- FAASW Nasdaq
- Market Cap
- TNGX 735.0M
- FAASW N/A
- IPO Year
- TNGX N/A
- FAASW 2021
- Fundamental
- Price
- TNGX $6.64
- FAASW $0.12
- Analyst Decision
- TNGX Strong Buy
- FAASW
- Analyst Count
- TNGX 8
- FAASW 0
- Target Price
- TNGX $15.14
- FAASW N/A
- AVG Volume (30 Days)
- TNGX 885.7K
- FAASW N/A
- Earning Date
- TNGX 11-06-2024
- FAASW N/A
- Dividend Yield
- TNGX N/A
- FAASW N/A
- EPS Growth
- TNGX N/A
- FAASW N/A
- EPS
- TNGX N/A
- FAASW N/A
- Revenue
- TNGX $42,509,000.00
- FAASW N/A
- Revenue This Year
- TNGX $18.15
- FAASW N/A
- Revenue Next Year
- TNGX N/A
- FAASW N/A
- P/E Ratio
- TNGX N/A
- FAASW N/A
- Revenue Growth
- TNGX 26.16
- FAASW N/A
- 52 Week Low
- TNGX $6.33
- FAASW N/A
- 52 Week High
- TNGX $13.01
- FAASW N/A
- Technical
- Relative Strength Index (RSI)
- TNGX 37.15
- FAASW N/A
- Support Level
- TNGX $6.83
- FAASW N/A
- Resistance Level
- TNGX $7.47
- FAASW N/A
- Average True Range (ATR)
- TNGX 0.37
- FAASW 0.00
- MACD
- TNGX 0.11
- FAASW 0.00
- Stochastic Oscillator
- TNGX 27.31
- FAASW 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About FAASW DigiAsia Corp. Warrant
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.